Meta-analysis of effect and safety of standard regimens and weekly regimens of topotecan treating NSCLC

CAI Heping; WANG Zhuo

doi:10.3969/j.issn.1006-0111.2014.01.006

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To compare the effect and safety of the two regimens of topotecan by means of Meta-analysis, in order to give evidences for doctors when selecting regimens. Methods All the studies that have been searched in Pub Med from setup data base to 2013-07-10 were evaluated strictly and meta-analysis was used to study the effect and safety of two regimens contain standard regimens and weekly regimens. The odds radio(OR) was calculate for incidence of efficiency and safety of two regimens. Results Totally 3 studies including 288 cases were analyzed in efficiency. 17 cases were effective in 165 cases of weekly regimens; 21 cases were effective in 123 cases of standard regimens. Totally 2 studies including 132 cases were analyzed in safety. 89 cases were in weekly regimens. Of which 26 cases of Ⅲ/Ⅳ neutropenia and 17cases of Ⅲ/Ⅳ low-hemoglobin and 32 cases of Ⅲ/Ⅳ thrombopenia. 43 cases were in standard regimens. Of which 39 cases of Ⅲ/Ⅳ neutropenia and 24 cases of Ⅲ/Ⅳ low-hemoglobin and 32 cases of Ⅲ/Ⅳ thrombopenia. The pooled OR of efficiency was 0.49 with a 95% confidence interval(0.23-1.01);the pooled OR of Ⅲ/Ⅳ neutropenia was 0.04 with a 95% confidence interval(0.01-0.14); the pooled OR of Ⅲ/Ⅳ low-hemoglobin was 0.27 with a 95% confidence interval(0.11-0.63); the pooled OR of Ⅲ/Ⅳ thrombopenia was 0.12 with a 95% confidence interval(0.04-0.32). Conclusion Weekly regimens group compared to standard regimens group in efficiency had no statistical significance; Weekly regimens group compared to standard regimens group for preventing Ⅲ/Ⅳ neutropenia, Ⅲ/Ⅳ low-hemoglobin and Ⅲ/Ⅳ thrombopenia had statistical significance. Weekly regimens group was better to standard regimens group for preventing Ⅲ/Ⅳ neutropenia, Ⅲ/Ⅳ low-hemoglobin and Ⅲ/Ⅳ thrombopenia.

Meta-analysis of effect and safety of standard regimens and weekly regimens of topotecan treating NSCLC

Department of Pharmacy, Changhai Hospital Afilliated to Second Military Medical University, Shanghai 200433, China

Received Date: 2013-12-11

Rev Recd Date: 2014-01-08

Key words:

Abstract: Objective To compare the effect and safety of the two regimens of topotecan by means of Meta-analysis, in order to give evidences for doctors when selecting regimens. Methods All the studies that have been searched in Pub Med from setup data base to 2013-07-10 were evaluated strictly and meta-analysis was used to study the effect and safety of two regimens contain standard regimens and weekly regimens. The odds radio(OR) was calculate for incidence of efficiency and safety of two regimens. Results Totally 3 studies including 288 cases were analyzed in efficiency. 17 cases were effective in 165 cases of weekly regimens; 21 cases were effective in 123 cases of standard regimens. Totally 2 studies including 132 cases were analyzed in safety. 89 cases were in weekly regimens. Of which 26 cases of Ⅲ/Ⅳ neutropenia and 17cases of Ⅲ/Ⅳ low-hemoglobin and 32 cases of Ⅲ/Ⅳ thrombopenia. 43 cases were in standard regimens. Of which 39 cases of Ⅲ/Ⅳ neutropenia and 24 cases of Ⅲ/Ⅳ low-hemoglobin and 32 cases of Ⅲ/Ⅳ thrombopenia. The pooled OR of efficiency was 0.49 with a 95% confidence interval(0.23-1.01);the pooled OR of Ⅲ/Ⅳ neutropenia was 0.04 with a 95% confidence interval(0.01-0.14); the pooled OR of Ⅲ/Ⅳ low-hemoglobin was 0.27 with a 95% confidence interval(0.11-0.63); the pooled OR of Ⅲ/Ⅳ thrombopenia was 0.12 with a 95% confidence interval(0.04-0.32). Conclusion Weekly regimens group compared to standard regimens group in efficiency had no statistical significance; Weekly regimens group compared to standard regimens group for preventing Ⅲ/Ⅳ neutropenia, Ⅲ/Ⅳ low-hemoglobin and Ⅲ/Ⅳ thrombopenia had statistical significance. Weekly regimens group was better to standard regimens group for preventing Ⅲ/Ⅳ neutropenia, Ⅲ/Ⅳ low-hemoglobin and Ⅲ/Ⅳ thrombopenia.

HTML

Reference (8)

[1]	Tomicic MT, Christmann M, Kaina B.Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival[J].Cancer Res,2005,65(19):8920-8926.
[2]	Armstrong DK, Spriggs D, Levin J, et al.Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer:an integrated analysis[J].Oncologist,2005,10(9):686-694.
[3]	Gordon AN, Fleagle JT, Guthrie D,et al.Recurrent epithelial ovarian carcinoma:a randomized phaseⅢ study of pegylated liposomal doxorubicin versus topotecan[J].J Clin Oncol,2001,19(14):3312-3322.
[4]	Vandenput I, Amant F, Neven P, et al.Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer[J].Int J Gynecol Cancer,2007,17(1):83-87.
[5]	Abushahin F, Singh DK, Lurain JR,et al.Weekly topotecan for recurrent platinum resistant ovarian cancer[J].Gynecol Oncol,2008,108(1):53-57.
[6]	Herzog TJ, Sill MW, Walker JL, et al.A phase Ⅱ study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer:a gynecologic oncology group study (GOG 146Q)[J].Gynecol Oncol,2011,120(3):454-458.
[7]	Sehouli J, Stengel D, Harter P,et al.Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer:a randomized multicenter phase Ⅱ trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group[J].J Clin Oncol,2011,29(2):242-248.
[8]	刘勇,席青松,赵荆,等.两种方案治疗难治/耐药型小细胞肺癌比较[J].药物与临床,2011,30(5):598-601.

Message Board

Meta-analysis of effect and safety of standard regimens and weekly regimens of topotecan treating NSCLC

doi: 10.3969/j.issn.1006-0111.2014.01.006

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views